Patents by Inventor Charles Bloomfield

Charles Bloomfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11293198
    Abstract: The device is comprised of two panels in the shape of “L”s that are interwoven with each other when they are placed on the sides of a fence. The device is secured to the ground through a series of holes for that purpose. Additionally, an expander has been placed on the section of the device, both vertical and horizontal, to address the issue of uneven terrain. A row of embedded lights is installed in each of the horizontal panels to provide additional illumination. Alternatively, a series of embedded wires may be installed in the horizontal panels that rest on the ground to provide a small (but not deadly) shock to prevent animals from entering the yard or preventing a family pet from leaving the yard.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: April 5, 2022
    Inventor: Charles Bloomfield
  • Publication number: 20210363777
    Abstract: The device is comprised of two panels in the shape of “L”s that are interwoven with each other when they are placed on the sides of a fence. The device is secured to the ground through a series of holes for that purpose. Additionally, an expander has been placed on the section of the device, both vertical and horizontal, to address the issue of uneven terrain. A row of embedded lights is installed in each of the horizontal panels to provide additional illumination. Alternatively, a series of embedded wires may be installed in the horizontal panels that rest on the ground to provide a small (but not deadly) shock to prevent animals from entering the yard or preventing a family pet from leaving the yard.
    Type: Application
    Filed: May 21, 2020
    Publication date: November 25, 2021
    Inventor: Charles Bloomfield
  • Patent number: 10428551
    Abstract: The device is comprised of two panels in the shape of “L”s that are interwoven with each other when they are placed on the sides of a fence. The device is secured to the ground through a series of holes for that purpose. Additionally, an expander has been placed on the section of the device, both vertical and horizontal, to address the issue of uneven terrain.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: October 1, 2019
    Inventor: Charles Bloomfield
  • Patent number: 10112926
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: October 30, 2018
    Assignee: Novartis AG
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Publication number: 20180243297
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 26, 2018
    Publication date: August 30, 2018
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Patent number: 10004732
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: June 26, 2018
    Assignee: Novartis AG
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Publication number: 20180125849
    Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.
    Type: Application
    Filed: January 10, 2018
    Publication date: May 10, 2018
    Inventors: Graham Charles Bloomfield, Ian Bruce, Brian Cox, Lee Edwards, Judy Fox Hayler, Catherine Howsham
  • Patent number: 9643983
    Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: May 9, 2017
    Assignee: Novartis AG
    Inventors: Gurdip Bhalay, Emma Budd, Graham Charles Bloomfield, Stephen Paul Collingwood, Andrew Dunstan, Lee Edwards, Peter Gedeck, Catherine Howsham, Peter Hunt, Thomas Anthony Hunt, Paul Oakley, Nichola Smith
  • Publication number: 20170042889
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 16, 2017
    Applicant: NOVARTIS AG
    Inventors: Benjamin Richard BELLENIE, Graham Charles BLOOMFIELD, Ian BRUCE, Andrew James CULSHAW, Edward Charles HALL, Gregory John HOLLINGWORTH, James NEEF, Matthew SPENDIFF, Simon James WATSON
  • Publication number: 20170037032
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 9, 2017
    Applicant: NOVARTIS AG
    Inventors: Benjamin Richard BELLENIE, Graham Charles BLOOMFIELD, Ian BRUCE, Andrew James CULSHAW, Edward Charles HALL, Gregory John HOLLINGWORTH, James NEEF, Matthew SPENDIFF, Simon James WATSON
  • Publication number: 20160303132
    Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.
    Type: Application
    Filed: June 27, 2016
    Publication date: October 20, 2016
    Applicant: Novartis AG
    Inventors: Ian Bruce, Judy Fox Hayler, Graham Charles Bloomfield, Lee Edwards, Brian Cox, Catherine Howsham
  • Patent number: 9303035
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: April 5, 2016
    Assignee: Novartis AG
    Inventors: Mahbub Ahmed, Alexander Ashall-Kelly, Graham Charles Bloomfield, Louisa Gueritz, Jeffrey McKenna, Joseph McKenna, Simon Mutton, Rakesh Parmar, Jon Sheperd, Paul Wright
  • Publication number: 20160068546
    Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: September 8, 2015
    Publication date: March 10, 2016
    Applicant: Novartis AG
    Inventors: Gurdip BHALAY, Emma BUDD, Graham Charles BLOOMFIELD, Stephen Paul COLLINGWOOD, Andrew DUNSTAN, Lee EDWARDS, Peter GEDECK, Catherine HOWSHAM, Peter HUNT, Thomas Anthony HUNT, Paul OAKLEY, Nichola SMITH
  • Patent number: 9139586
    Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: September 22, 2015
    Assignee: Novartis AG
    Inventors: Gurdip Bhalay, Emma Budd, Graham Charles Bloomfield, Stephen Paul Collingwood, Andrew Dunstan, Lee Edwards, Peter Gedeck, Catherine Howsham, Peter Hunt, Thomas Anthony Hunt, Paul Oakley, Nichola Smith
  • Patent number: 8901134
    Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: December 2, 2014
    Assignee: Novartis AG
    Inventors: Graham Charles Bloomfield, Ian Bruce, Brian Cox, Lee Edwards, Judy Fox Hayler, Catherine Howsham
  • Publication number: 20140235632
    Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Applicant: NOVARTIS AG
    Inventors: Graham Charles Bloomfield, Ian Bruce, Brian Cox, Lee Edwards, Judy Fox Hayler, Catherine Howsham
  • Publication number: 20140171412
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: December 17, 2013
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: Mahbub AHMED, Alexander ASHALL-KELLY, Graham Charles BLOOMFIELD, Louisa GUERITZ, Jeffrey MCKENNA, Joseph MCKENNA, Simon MUTTON, Rakesh PARMAR, Jon SHEPERD, Paul WRIGHT
  • Publication number: 20140171421
    Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: Gurdip Bhalay, Emma Budd, Graham Charles Bloomfield, Stephen Paul Collingwood, Andrew Dunstan, Lee Edwards, Peter Gedeck, Catherine Howsham, Peter Hunt, Thomas Anthony Hunt, Paul Oakley, Nichola Smith
  • Patent number: 8697687
    Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: April 15, 2014
    Assignee: Novartis AG
    Inventors: Gurdip Bhalay, Emma Budd, Graham Charles Bloomfield, Stephen Paul Collingwood, Andrew Dunstan, Lee Edwards, Peter Gedeck, Catherine Howsham, Peter Hunt, Thomas Anthony Hunt, Paul Oakley, Nichola Smith
  • Publication number: 20140051698
    Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.
    Type: Application
    Filed: October 9, 2013
    Publication date: February 20, 2014
    Applicant: NOVARTIS AG
    Inventors: Ian Bruce, Judy Fox Hayler, Graham Charles Bloomfield, Lee Edwards, Brian Cox, Catherine Howsham